Revenue Change
+6.6M
Operating Income YoY
+16.28%
Net Income YoY
+3.20%
Net Margin Δ
+421782 bps
Net income bridge for Ovid Therapeutics (OVID) — TTM through Q1 2026 vs TTM through Q1 2025
Δ Net income: $806.00K+3.20%
Profit bridge breakdown for Ovid Therapeutics (OVID) — TTM through Q1 2026 vs TTM through Q1 2025
| Driver | Contribution | % of Δ |
|---|---|---|
| Prior Net Income | −$24.97M | — |
| Revenue | $6.57M | +815.6% |
| Cost of Revenue | −$35.00K | -4.3% |
| Operating Expenses | $2.74M | +340.1% |
| Other Income / Expense | −$8.47M | -1051.4% |
| Income Tax | $0.00 | 0.0% |
| Net Loss | −$24.17M | — |
- Prior Net Income−$24.97M
- Revenue$6.57M
- Cost of Revenue−$35.00K
- Operating Expenses$2.74M
- Other Income / Expense−$8.47M
- Income Tax$0.00
- Net Loss−$24.17M
Identity check: drivers reconcile to ΔNI within $0.00 ✓
Want the full P&L structure?Income Statement Waterfall
Frequently asked questions
Data & methodology
Ovid Therapeutics (OVID) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement